The application of LCN2 specific monoclonal antibody in the time window can significantly reduce the levels of LCN2 mRNA and protein and pro-inflammatory mediators, reduce neurological deficits, cerebral infarction, edema, BBB leakage and neutrophil infiltration, and improve the functional prognosis of stroke [42]. The gene discussed is LCN2; the disease is brain infarction.